secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040936
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent Q2 net loss $29.1M; cash $431.2M; NVL-655 data expected Q4 2023
------------------------------------------------------------------------

- Net loss $29.1M ($0.51/share); R&D $25.9M, G&A $8.1M for Q2 2023.
- Cash, cash equivalents and marketable securities $431.2M as of June 30, 2023; runway into H2 2025.
- Preliminary dose-escalation data for NVL-655 from ALKOVE-1 trial expected at medical meeting in Q4 2023.
- NVL-520 ARROS-1 trial progressing toward RP2D; NVL-330 HER2 inhibitor advancing through IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017023040936/0000950170-23-040936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017023040936/nuvl-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer